F
Flavia Longo
Researcher at Sapienza University of Rome
Publications - 121
Citations - 7275
Flavia Longo is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 24, co-authored 121 publications receiving 6421 citations. Previous affiliations of Flavia Longo include Policlinico Umberto I.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino,Olga Martelli,Massimo Broggini,Gabriella Farina,Silvio Veronese,Eliana Rulli,F. Bianchi,Anna Cecilia Bettini,Flavia Longo,Luca Moscetti,M. Tomirotti,Mirko Marabese,Monica Ganzinelli,Calogero Lauricella,Roberto Labianca,Irene Floriani,Giuseppe Giaccone,Valter Torri,A. Scanni,Silvia Marsoni +19 more
TL;DR: Chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours and progression-free survival was significantly better with docetaxel than with erlot inib.
Journal ArticleDOI
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo,Cristina Raimondi,M. Mancini,Salvatore Caponnetto,Angela Gradilone,Orietta Gandini,Maria Mastromartino,Gabriella Del Bene,Alessandra Anna Prete,Flavia Longo,Enrico Cortesi,Paola Gazzaniga +11 more
TL;DR: The persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape, and patients could be dichotomized into two groups based PD- L1 expression on C TCs, which suggests that the persistence ofPD-L2 negative CTCS all obtained a clinical benefit, while patients with PD-CTCs all experienced progressive disease.
Journal ArticleDOI
Long-term outcome after multimodality treatment for stage III thymic tumors.
Federico Venuta,Erino A. Rendina,Flavia Longo,Tiziano De Giacomo,Marco Anile,Edoardo Mercadante,Luigi Ventura,Mattia Falchetto Osti,Federico Francioni,Giorgio F. Coloni +9 more
TL;DR: Multimodality treatment with induction chemotherapy (when required) and adjuvant chemoradiotherapy offers encouraging results for stage III thymic tumors; the outcome is more favorable for cortical thymoma and well-differentiatedThymic carcinoma.
Journal ArticleDOI
Whole-Tumor Perfusion CT in Patients with Advanced Lung Adenocarcinoma Treated with Conventional and Antiangiogenetic Chemotherapy: Initial Experience
Francesco Fraioli,Michele Anzidei,Fulvio Zaccagna,M. Mennini,Goffredo Serra,Bruno Gori,Flavia Longo,Carlo Catalano,Roberto Passariello +8 more
TL;DR: Perfusion CT imaging may allow evaluation of lung cancer angiogenesis demonstrating alterations in vascularity following treatment, and Pearson correlation coefficient showed a significant correlation between baseline values of blood flow and blood volume and CT numbers.